Ramon Lecumberri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6630828/publications.pdf

Version: 2024-02-01

112 papers	4,032 citations	147801 31 h-index	123424 61 g-index
127 all docs	127 docs citations	127 times ranked	4466 citing authors

#	Article	IF	Citations
1	Consenso multidisciplinar para el manejo de la tromboembolia de pulmÃ³n. Archivos De Bronconeumologia, 2022, 58, 246-254.	0.8	12
2	Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial. Thrombosis and Haemostasis, 2022, 122, 295-299.	3.4	40
3	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leukemia and Lymphoma, 2022, 63, 538-550.	1.3	8
4	Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHHâ€“SETH. Clinical and Translational Oncology, 2022, 24, 770-783.	2.4	1
5	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. Viruses, 2022, 14, 178.	3.3	18
6	CM-352 EFFICACY IN A MOUSE MODEL OF ANTICOAGULANT-ASSOCIATED INTRACRANIAL HAEMORRHAGE. Thrombosis and Haemostasis, 2022, 0, .	3.4	0
7	Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors. Thrombosis and Haemostasis, 2022, 122, 1594-1602.	3.4	8
8	[Translated article] Multidisciplinary consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, 2022, 58, T246-T254.	0.8	4
9	Long-Term Outcome of Critically Ill Advanced Cancer Patients Managed in an Intermediate Care Unit. Journal of Clinical Medicine, 2022, 11, 3472.	2.4	1
10	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. HemaSphere, 2022, 6, e750.	2.7	29
11	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncology, The, 2022, 23, e334-e347.	10.7	138
12	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Leukemia, 2021, 35, 245-249.	7.2	10
13	Inside the Thrombus: Association of Hemostatic Parameters With Outcomes in Large Vessel Stroke Patients. Frontiers in Neurology, 2021, 12, 599498.	2.4	8
14	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer Journal, 2021, 11, 34.	6.2	39
15	Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. Journal of the American College of Cardiology, 2021, 77, 2987-3001.	2.8	69
16	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Blood, 2021, 138, 1583-1589.	1.4	11
17	Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores. TH Open, 2021, 05, e319-e328.	1.4	5
18	Multidisciplinary consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, 2021, , .	0.8	0

#	Article	IF	Citations
19	Impact of the mutation profile on thrombotic risk in cancer patients. Revista Clínica Espanõla, 2021, 222, 93-93.	0.5	0
20	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. Viruses, 2021, 13, 2128.	3.3	4
21	Reply. Journal of the American College of Cardiology, 2021, 78, e129.	2.8	0
22	Performance of 18F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. Thrombosis Research, 2020, 194, 153-157.	1.7	3
23	Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia. Thrombosis Research, 2020, 195, 139-145.	1.7	12
24	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematology,the, 2020, 7, e746-e755.	4.6	21
25	Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 163-167.	3.0	27
26	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	3.8	60
27	Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey. Blood, 2020, 136, 11-11.	1.4	0
28	New mechanisms in venous thrombosis: Immunothrombosis. Medicina ClÃnica (English Edition), 2019, 153, 78-81.	0.2	0
29	Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies. TH Open, 2019, 03, e153-e156.	1.4	0
30	Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. Thrombosis and Haemostasis, 2019, 119, 1409-1418.	3.4	8
31	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	10.7	458
32	Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis. Thrombosis Research, 2019, 176, 79-84.	1.7	8
33	Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience. Clinical and Translational Oncology, 2019, 21, 805-809.	2.4	3
34	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Leukemia, 2019, 33, 1256-1267.	7.2	20
35	Nuevos mecanismos en la trombosis venosa: inmunotrombosis. Medicina ClÃnica, 2019, 153, 78-81.	0.6	6
36	Causes of Death in Patients with Venous Thromboembolism Anticoagulated with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis, 2018, 44, 377-387.	2.7	9

#	Article	IF	Citations
37	Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism. TH Open, 2018, 02, e428-e436.	1.4	3
38	Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelinesâ€"A Multidisciplinary (SEMIâ€"SEOMâ€"SETH) Expert Consensus. TH Open, 2018, 02, e373-e386.	1.4	17
39	Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study. PLoS ONE, 2018, 13, e0200220.	2.5	11
40	Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma Cell (PC) Development. Blood, 2018, 132, 188-188.	1.4	0
41	Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM). Blood, 2018, 132, 3170-3170.	1.4	0
42	Firstâ€line use of rituximab correlates with increased overall survival in late postâ€transplant lymphoproliferative disorders: retrospective, singleâ€centre study. European Journal of Haematology, 2017, 98, 38-43.	2.2	14
43	FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. Clinical and Translational Oncology, 2017, 19, 997-1009.	2.4	11
44	Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. BMJ Open, 2017, 7, e015562.	1.9	14
45	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. American Journal of Medicine, 2017, 130, 482.e1-482.e9.	1.5	9
46	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2017, 167, 410.	3.9	96
47	Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 2076-2079.	3.8	56
48	Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2017, 5, 18-24.e1.	1.6	15
49	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2017, 151, 564-571.	0.8	51
50	The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. American Journal of Medicine, 2017, 130, 337-347.	1.5	83
51	Inducing heat shock protein 70 expression provides a robust anti-thrombotic effect with minimal bleeding risk. Thrombosis and Haemostasis, 2017, 117, 1722-1729.	3.4	10
52	Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study. European Journal of Haematology, 2016, 97, 128-136.	2.2	2
53	Antidotes for the new oral anticoagulants: Reality and expectations. Medicina ClÃnica (English) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.2	0
54	Implementation of a management protocol for massive bleeding reduces mortality in non-trauma patients: Results from a single centre audit. Medicina Intensiva, 2016, 40, 550-559.	0.7	18

#	Article	IF	Citations
55	BÃºsqueda de cÃ¡ncer oculto en pacientes con tromboembolismo venoso: un dilema por resolver. Angiologia, 2016, 68, 456-458.	0.0	0
56	Short Leukocyte Telomere Length Is Associated With Cardioembolic Stroke Risk in Patients With Atrial Fibrillation. Stroke, 2016, 47, 863-865.	2.0	26
57	Cancer screening after unprovoked venous thrombosis. Lancet Oncology, The, 2016, 17, 128-129.	10.7	4
58	Directâ€acting oral anticoagulants: pharmacology, indications, management, and future perspectives. European Journal of Haematology, 2015, 95, 389-404.	2.2	70
59	Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. Journal of Thrombosis and Haemostasis, 2015, 13, 1010-1018.	3.8	77
60	Atypical bullous pemphigoid with extensive cutaneous and mucosal erosions associated with chronic lymphocytic leukemia. Journal of Dermatology, 2015, 42, 1128-1129.	1.2	2
61	Spectrum of Atypical Clinical Presentations in Patients with Biallelic PRF1 Missense Mutations. Pediatric Blood and Cancer, 2015, 62, 2094-2100.	1.5	38
62	Specific Antidotes in Development for Reversal of Novel Anticoagulants: A Review. Recent Patents on Cardiovascular Drug Discovery, 2015, 9, 2-10.	1.5	50
63	ReexposiciÃ³n temprana a heparina durante el trasplante cardiaco de pacientes con trombocitopenia inducida por heparina y asistencia ventricular. Revista Espanola De Cardiologia, 2015, 68, 638-640.	1.2	3
64	A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients withÂcatheter-related thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 243-250.e1.	1.6	28
65	Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 490-500.	2.0	53
66	Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study. Thrombosis Research, 2015, 136, 1145-1148.	1.7	9
67	Short-term Heparin Re-exposure During Heart Transplantation in Patients With Ventricular Assist Devices and Acute Heparin-induced Thrombocytopenia. Revista Espanola De Cardiologia (English Ed), 2015, 68, 638-640.	0.6	0
68	C0374: Venous Thromboembolism in Hospitalised Cancer Patients Despite Electronic Alerts and Appropriate Prophylaxis with LMWH. Should We Consider Higher Doses in Some Patients?. Thrombosis Research, 2014, 133, S4-S5.	1.7	0
69	C0122: Identification of 6 Mutations in the Protein C Gene (PROC) in a Panel of 83 Spanish Families with Protein C Deficiency. Thrombosis Research, 2014, 133, S78.	1.7	0
70	Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vascular Health and Risk Management, 2014, 10, 627.	2.3	23
71	Direct oral anticoagulants in the treatment of acute venous thromboembolism: A systematic review and meta-analysis. Thrombosis Research, 2014, 134, 774-782.	1.7	113
72	Screening for occult malignancy with FDGâ€PET/CT in patients with unprovoked venous thromboembolism. International Journal of Cancer, 2013, 133, 2157-2164.	5.1	24

#	Article	IF	Citations
73	Consenso nacional sobre el diagnÃ³stico, estratificaciÃ³n de riesgo y tratamiento de los pacientes con tromboembolia pulmonar. Archivos De Bronconeumologia, 2013, 49, 534-547.	0.8	70
74	Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study. Thrombosis Research, 2013, 132, 666-670.	1.7	57
75	International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2013, 11, 56-70.	3.8	469
76	International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. Journal of Thrombosis and Haemostasis, 2013, 11, 71-80.	3.8	252
77	Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission. Clinical Cancer Research, 2013, 19, 4770-4779.	7.0	77
78	High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. Thrombosis and Haemostasis, 2013, 110, 184-190.	3.4	19
79	Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 834-843.	3.4	94
80	Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vascular Health and Risk Management, 2013, 9, 207.	2.3	26
81	POEMS syndrome with severe neurological damage clinically recovered with lenalidomide. Haematologica, 2012, 97, 320-322.	3.5	29
82	Screening for occult malignancy with 18-F-FDG-PET/CT in patients with unprovoked venous thromboembolism. Thrombosis Research, 2012, 129, S176.	1.7	0
83	E-alerts for the prevention of venous thromboembolism in onco-hematological inpatients: pilot evaluation of reasons for physicians' refusal of pharmacological thromboprophylaxis. Thrombosis Research, 2012, 129, S181.	1.7	0
84	Abstract related to PL-22 Guidelines for antithrombotics in cancer patients. Thrombosis Research, 2012, 129, S194.	1.7	0
85	C0235 Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency. Thrombosis Research, 2012, 130, S110-S111.	1.7	0
86	Discovery of Anticoagulant Drugs: A Historical Perspective. Current Drug Discovery Technologies, 2012, 9, 83-104.	1.2	96
87	International Clinical Practice Guidelines for the Treatment and Prophylaxis of Thrombosis Associated with Central Venous Catheters in Patients with Cancer. Blood, 2012, 120, 4357-4357.	1.4	0
88	P.32 The TEAM project: Spanish Registry of Thromboembolic Disease (TD) related with hormonal treatments, pregnancy, obstetrics complications or assisted reproductive procedures in women (ARP). Thrombosis Research, 2011, 127, S136-S137.	1.7	0
89	P.33 Study of variability in the management of thromboembolic disease (TD) in women in Spain: national multicenter study. Thrombosis Research, 2011, 127, S137.	1.7	0
90	Effect of the time of diagnosis on outcome in patients with acute venous thromboembolism. Thrombosis and Haemostasis, 2011, 105, 45-51.	3.4	13

#	Article	IF	Citations
91	Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients. Journal of Thrombosis and Haemostasis, 2011, 9, 1108-1115.	3.8	20
92	New parenteral anticoagulants in development. Therapeutic Advances in Cardiovascular Disease, 2011, 5, 33-59.	2.1	46
93	Clinical characteristics of patients with factor V Leiden or prothrombin G20210A and a first episode of venous thromboembolism. Findings from the RIETE Registry. Thrombosis Research, 2010, 126, 283-286.	1.7	16
94	OC-08 Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. Thrombosis Research, 2010, 125, S163.	1.7	5
95	PO-02 Incidence of venous thromboembolism and prophylaxis use in ambulatory cancer patients receiving chemotherapy. Thrombosis Research, 2010, 125, S166.	1.7	0
96	Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thrombosis Research, 2009, 124, 174-177.	1.7	78
97	New Anticoagulants: Focus on Venous Thromboembolism. Current Vascular Pharmacology, 2009, 7, 309-329.	1.7	26
98	ABO blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica, 2008, 93, 729-734.	3.5	29
99	Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Thrombosis and Haemostasis, 2008, 100, 905-911.	3.4	56
100	D-dimer level is not a prognostic biomarker specific of pulmonary embolism. Critical Care Medicine, 2008, 36, 653.	0.9	3
101	Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients. Thrombosis and Haemostasis, 2008, 100, 699-704.	3.4	92
102	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood, 2007, 109, 4258-4263.	1.4	104
103	D-dimer levels correlate with mortality in patients with acute pulmonary embolism: Findings from the RIETE registry. Critical Care Medicine, 2007, 35, 1937-1941.	0.9	67
104	3B.1 Epidemiology of cancer and thrombosis in women â€“ findings from the RIETE Registry. Thrombosis Research, 2007, 119, S30-S32.	1.7	0
105	Venous thromboembolism during pregnancy or postpartum: Findings from the RIETE Registry. Thrombosis and Haemostasis, 2007, 97, 186-190.	3.4	111
106	A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood, 2006, 108, 177-183.	1.4	58
107	Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study. Journal of Thrombosis and Haemostasis, 2006, 4, 2504-2508.	3.8	8
108	Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies. Haematologica, 2005, 90, 1258-66.	3.5	19

#	Article	IF	Citations
109	Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis. Journal of Thrombosis and Haemostasis, 2004, 2, 1581-1587.	3.8	30
110	Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 143, 178-181.	1.0	18
111	Evaluation of the factor V HR2 haplotype as a risk factor for ischemic cerebrovascular disease. Haematologica, 2003, 88, 236-7.	3.5	6
112	Acquired inhibitor of the intrinsic pathway in a non-haemophilic patient. control of bleeding by recombinant factor viia. British Journal of Haematology, 2002, 119, 284-285.	2.5	3